As of February 13 at 1:23:05 PM EST. Market Open.

Bashar Masri, a Palestinian-American billionaire, has quietly positioned himself as a key player in the Trump administration’s post-war plans for Gaza. According to diplomatic sources ...

The firm decreased its portfolio allocation in TXG by 12.08% over the last quarter. Sumitomo Mitsui Trust Holdings holds 5,713K shares representing 5.34% ownership of the company. In its prior ...

Serge Saxonov, the Chief Executive Officer of $TXG, sold 7,942 shares of the company on 02-28-2025 for an estimated $84,393. We received data on the trade from a ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.

Benjamin J. Hindson, the See Remarks of $TXG, sold 4,573 shares of the company on 02-24-2025 for an estimated $50,602. We received data on the trade from a recent SEC ...

10x Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

10x Genomics Price Performance Shares of TXG opened at $12.31 on Tuesday. The firm has a market cap of $1.49 billion, a PE ratio of -8.05 and a beta of 1.85. The stock’s fifty day moving average ...

Citi lowered the firm’s price target on 10x Genomics (TXG) to $15 from $20 and keeps a Buy rating on the shares. The firm updated models in the life science tools and diagnostics group post the ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa ...

Mushir al-Masri was speaking to CNN from Gaza after the White House confirmed it had negotiated directly with Hamas with the aim of securing the release of hostages in Gaza, breaking a long ...